{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "hCG",
    "short_name": "hCG",
    "aliases": [
      "human chorionic gonadotropin",
      "chorionic gonadotropin",
      "pregnyl"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what hCG is and the general domain where it appears."
    },
    "status": {
      "category": "approved_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how hCG appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "hCG is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for hCG",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "needs_prescription": true,
    "meta": {
      "priority": "normal",
      "notes_seed": "FDA-approved chorionic gonadotropin hormone (Rx); include only label-level indications; no protocols."
    },
    "topics": {
      "primary": [
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "hcg"
  },
  "canonical_name": "Hcg",
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "hCG is a prescription hormone used in specific fertility and endocrine contexts. It is not a general wellness peptide; misuse can disrupt hormones, fertility, and mood, and carries meaningful risk.",
    "benefits": [
      "clinical relevance in fertility treatment and certain hypogonadism protocols (medical supervision)",
      "physiology relevance in LH-like signaling discussions"
    ],
    "side_effects_common": [
      "mood changes or irritability",
      "headache",
      "water retention or bloating",
      "breast tenderness or hormonal discomfort"
    ],
    "side_effects_serious": [
      "blood clot symptoms (leg swelling/pain, sudden shortness of breath)",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)",
      "severe abdominal/pelvic pain or rapid swelling (urgent evaluation)"
    ],
    "who_should_be_cautious": [
      "people with hormone-sensitive cancers or tumor risk contexts",
      "people with clotting history or strong clot risk factors",
      "pregnant or breastfeeding individuals (medical use only, specialist context)",
      "adolescents (puberty/endocrine axis disruption risk)"
    ],
    "schema_version": "practical_block_v1"
  }
}
